Hemas Holdings Plc

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: LK0337N00002
LKR
36.50
0.5 (1.39%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Hemas Holdings Plc stock-summary
stock-summary
Hemas Holdings Plc
Pharmaceuticals & Biotechnology
Hemas Holdings PLC (Hemas) is a Sri Lanka-based pharmaceuticals company engaged in healthcare, leisure and transportation services. The Company operates in various segments, such as FMCG, Healthcare, Leisure, Transportation, Power and others. The FMCG business sector manufactures and markets personal care and home care branded products. Its Healthcare sector is a distributor of pharmaceuticals, surgical and diagnostic products in Sri Lanka. Its Leisure sector consists of the Serendib Leisure Group of Hotels. The Transportation sector consists of the aviation business both in the passenger and cargo segments, its maritime business providing feeder operations and agency services for international shipping partners, its outbound travel agency services via Hemas Travels and its logistics business unit consists of integrated logistic services.
Company Coordinates stock-summary
Company Details
No 75, Braybrooke Place, Colombo 02 , COLOMBO None : 01
stock-summary
Tel: 94 11 4731713
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Husein Nuruddin Esufally
Non-Executive Chairman of the Board
Mr. Murtaza Esufally
Executive Director
Mr. Sriyan Wijeyeratne
Executive Director
Mr. Abbasally Esufally
Non-Executive Director
Mr. Imtiaz Esufally
Non-Executive Director
Dr. Sumith Ekanayake
Independent Director
Mr. Ramabadran Gopalakrishnan
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
28,526 Million
(Quarterly Results - Jun 2025)
Net Profit:
1,255 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

LKR 104,827 Million (Large Cap)

stock-summary
P/E

12.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.01

stock-summary
Return on Equity

17.98%

stock-summary
Price to Book

2.06